560 results about "Lipofectamine" patented technology

The invention provides a gamma delta T cell preparation as well as a preparation method and application thereof, and belongs to the technical field of T cells. The liposome is prepared from the following raw materials in parts by weight: 15-20 parts of modified gamma delta T cell liposome, 1-3 parts of cell stimulating factors and 4-7 parts of culture medium freeze-dried powder, the modified gamma delta T cell lipidosome is prepared by embedding gamma delta T cells through lipidosome, coupling with acetylenic bond modified chitosan, and further mixing with MFAP4 protein and b4GALT1 protein. The culture medium freeze-dried powder is prepared by freeze-drying the culture medium in the engineering culture process of gamma delta T cells, and the cell stimulating factors are resveratrol and quercitrin. According to the gamma delta T cell preparation prepared by the invention, the survival ability and resistance of gamma delta T cells are improved, the anti-tumor activity of the gamma delta T cells is improved, and the gamma delta T cell preparation has relatively good antioxidant and anti-inflammatory effects, reduces the inhibition of inflammation on an immune system and has a very good treatment effect on pancreatic ductal adenocarcinoma.

The invention belongs to the technical field of biological medicine, and discloses a novel adjuvant recombinant herpes zoster vaccine and a preparation method thereof. The vaccine is composed of gE-gD protein and a liposome adjuvant, the liposome adjuvant is prepared by the following steps: co-dissolving 3D-MLA, phospholipid-containing components and steroid components in an organic solvent to form a film, hydrating and homogenizing with PBS, finally adding QS-21, and fixing the volume with PBS. According to the process, enhanced components are uniformly and stably anchored in a membrane phase micro-domain, and the particle structure is controllable. Under the same antigen dosage and detection caliber, the D28 GMC of the vaccine is obviously improved, and more sufficient and stronger primary humoral immune response is embodied.

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention discloses a specific cell targeted hybrid nano-delivery carrier and a preparation method and application thereof, and aims to solve the problems of insufficient specificity, off-target risk, low delivery efficiency and the like of an existing drug delivery system. And a bionic hybrid nano delivery platform with a natural targeting function and high drug loading capacity is constructed. The vector retains key receptor molecules and signal markers on a source cell membrane, and can actively identify and target corresponding cells; meanwhile, due to the introduction of the lipidosome, the yield and stability of the material are remarkably improved, and the immune clearance rate is reduced. Experimental results show that the nano-carrier shows good targeting and biocompatibility in various disease models, and has wide clinical application prospects in the aspects of tumor treatment, tissue repair, inflammation control, targeted imaging and the like.

The invention provides a nucleic acid aptamer and a screening method thereof, the aptamer is of an oligonucleotide DNA structure, the nucleotide sequence of the nucleic acid aptamer is the nucleotide sequence of any DNA fragment as shown in SEQ ID NO: 1-9, and the nucleic acid aptamer can specifically target cardiac muscle cells (CMs). According to the invention, a new strategy can be provided for clinical treatment of cardiovascular diseases, and meanwhile, bioactive molecules such as microRNA (miRNA), small interfering RNA (small interfering RNA, siRNA), lipidosome, microspheres, microcapsules and the like can be carried to be used as an intracellular drug delivery tool.

The invention relates to a preparation method and application of a blue copper peptide-PDRN composite freeze-dried efficacy core sphere steady-state delivery system, and belongs to the technical field of cosmetics. The invention provides a composite freeze-dried functional core sphere steady-state delivery system of a combination of blue copper peptide, PDRN and macromolecular active ingredients, an ordered and stable nano-assembly steady-state structural system is formed through multiple interaction among blue copper peptide, PDRN and macromolecules, and the problems of stability and compatibility of blue copper peptide are solved; secondly, a composite freeze-dried functional core ball based on a copper-blue peptide liposome inclusion compound is developed, and the transdermal absorption rate of copper-blue peptide is improved; thirdly, the blue copper peptide functional core ball based on excellent transdermal absorption rate is developed; finally, a processing technology for producing a blue copper peptide composite freeze-drying efficacy core sphere steady-state delivery system at low temperature in a whole process based on liquid nitrogen quick freezing is developed.

The invention relates to the technical field of organic synthesis and the technical field of fluorescent materials, in particular to a boron coordination salicylhydrazone double-state emission fluorophore as well as a preparation method and application of the boron coordination salicylhydrazone double-state emission fluorophore. The structure of the boron coordination salicylazone double-state emission fluorophore is shown as I, II or III; wherein R1 is selected from one of H, halogen atoms, diethylamino and thienyl, R2 is selected from one of H, halogen atoms, diethylamino and thienyl, and R3 is selected from one of aryl, 9, 9 '-spirobifluorenyl, alkoxy and halogen atoms. The boron coordination salicylazone double-state emission fluorophore is diversified in structure and good in solubility, has excellent photophysical properties and extremely high quantum yield, and also shows excellent biocompatibility and remarkable liposome targeting property at the same time. Moreover, the preparation method of the boron-coordinated salicylazone double-state emission fluorophore adopts a one-pot two-step method, is simple and convenient, is high in yield, is green and environment-friendly, and has a wide application prospect.

An mRNA vaccine encapsulated with lipid nanoparticles for PDCoV, a preparation method and an application thereof are provided, and the mRNA vaccine for PDCoV includes at least one of sequences as described in SEQ ID NO: 1-2; the lipid nanoparticle-encapsulated mRNA vaccines includes the mRNA vaccine, and lipids for encapsulating the mRNA vaccine, and the lipids are formed by mixing ionizable liposome, distearoyl phosphatidylcholine, cholesterol and PEG liposome.

The invention discloses basic amino acid modified 3S-PCL as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The basic amino acid modified 3S-PCL has a structural formula shown in the specification, wherein R is alkaline amino acid; m, m1 and m2 are all positive integers, and m, m1 and m2 are greater than or equal to 1. According to the invention, a basic amino acid modified three-arm polycaprolactone (3S-PCL) material is designed and synthesized, and the basic amino acid modified three-arm polycaprolactone (3S-PCL) material has good biocompatibility and can be used for lipid nanoparticle nucleic acid delivery instead of a cationic liposome. The preparation method of the basic amino acid modified 3S-PCL material is simple and rapid, and is especially suitable for industrial production. The lipid nanoparticles prepared by using the basic amino acid modified 3S-PCL material as a gene vector can realize efficient delivery of nucleic acid drugs.

The invention discloses application of an overexpressed carp lpla gene in regulation and control of expression of cyprinid fish tissue-related genes, and relates to the field of gene engineering, in particular to application of the overexpressed carp lpla gene in regulation and control of cyprinid fish tissue-related genes. The overexpressed carp lpla gene is applied to regulation and control of contents of lipid indexes of total cholesterol TC and triglyceride TG of different tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulation and control of fat marker genes lpla, ppar gamma, Fabp3, fast and acaca of livers and muscle tissues of cyprinid fishes. The invention further discloses application of the overexpressed carp lpla gene in regulating and controlling the relative expression quantity of carp liver cell fat metabolism related genes lpla, ppar gamma, Fabp3, fast, acaca, hsl and pnpla2. The overexpressed carp lpla gene can regulate and control lipid deposition in different tissues in zebra fish, and a research model is provided for lpla to regulate and control fat deposition and differentiation. According to the overexpressed carp lpla gene disclosed by the invention, lpla high-expression carp hepatocytes are obtained through a liposome transfection technology, so that fat key gene expression in the carp hepatocytes is changed.

The invention discloses an engineered bionic nucleic acid nano diagnosis and treatment agent as well as a preparation method and application thereof, relates to the technical field of biological targeting, and aims to solve the problems that an engineered macrophage membrane modified bionic nucleic acid nano diagnosis and treatment agent for oral squamous cell carcinoma is lacked in the prior art, and the curative effect on invasive tumors of the oral squamous cell carcinoma is poor. According to the engineering bionic nucleic acid nano diagnosis and treatment agent, a cationic lipid nucleic acid medicine is wrapped with a macrophage membrane, and PD1 shown as SEQ.ID.NO.1 is stably expressed on the macrophage membrane; the cationic lipid nucleic acid medicine is prepared by loading Cip2a siRNA (small interfering Ribonucleic Acid) on a cationic liposome. The bionic nucleic acid nano diagnosis and treatment agent has a huge application prospect in preparation of oral squamous cell carcinoma diagnosis kits and medicines.

The invention discloses a compound which is a compound as shown in a formula (I) or a stereoisomer, a tautomer, a solvate and a pharmaceutically acceptable salt of the compound as shown in the formula (I). As a liposome, the compound provided by the invention has high transfection efficiency, and especially can be used for delivering nucleic acid molecules (such as siRNA, mRNA and pDNA) to regulate expression of protein, or delivering CRISPR gene editing tools to realize knockout or repair of lesion genes.

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention discloses an immunogenic composition containing an adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises self-assembled gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the self-assembled gE virus-like nanoparticles are formed by polymerizing and assembling monomers; the monomers include VZV gE, a linker peptide (SGS), and a VZV gI polypeptide containing a Th epitope. The immunogenic composition can be applied to varicella-zoster virus vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, and the use of an immunopotentiator in the vaccine can be reduced, so that the clinical side reaction of the vaccine is lower; in addition, the vaccine can induce a gI specific antibody and gI specific CMI reaction, and the effectiveness of the vaccine can be further improved. In short, the immunogenic composition has good clinical application potential.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

The invention relates to a nanoparticle system for small intestine delivery, which is used for delivering exogenous miR-122-5p to the intestinal tract and comprises a miRNA-protamine compound inner core, a liposome middle layer wrapping the inner core and a p123 functional shell wrapping the liposome. Due to the adoption of the technical scheme, a nano-targeting delivery technology is combined with paternal epigenetic programming intervention for the first time, and a brand-new nano-drug treatment thought is provided for intergenerational genetic diseases caused by exposure of environmental adverse factors. By delivering exogenous miR-122-5p to the intestinal tract, the miRNA spectrum unbalanced due to exposure of paternal BaP can be directly improved.

The invention discloses a ganoderma lucidum lipid exosome containing a liver protection component and a preparation method and application thereof.The preparation method comprises the steps that the liver protection component is wrapped with a coarsely extracted ganoderma lucidum exosome, then the liver protection component is wrapped with lipidosome, and therefore a lipidosome-exosome-liver protection component three-layer structure is formed from outside to inside; in the three-layer structure, the outer layer liposome can protect the storage of the liver protection component and can improve the transmembrane transport efficiency, the middle layer exosome serves as a carrier and can reach a designated position to be released, and the inner layer contains the liver protection component and can improve the transmembrane transport efficiency. Cell cycle arrest can be prevented, antioxidant enzyme activity can be improved, cell membranes can be protected from oxidative damage, and redox steady state can be maintained to relieve cell aging. The prepared ganoderma lucidum lipid exosome containing the liver protection component realizes slow release synergy through a three-layer structure, and the action time of the active component is remarkably prolonged.

Provided herein are methods for making liposomal API formulations via continuous in-line diafiltration processes. Also provided herein are liposomal API formulations manufactured by the disclosed methods.

The invention discloses liposome nanoparticles as well as a preparation method and application thereof, and relates to the field of biological medicines. The liposome nanoparticle comprises a lipid compound modified with a fusion protein, the fusion protein comprises apolipoprotein E or polypeptide thereof and an antibody, the modification of the fusion protein not only can actively target cells, tissues or organs of corresponding ligands, but also can effectively improve the transfection efficiency and the targeting delivery capability of the liposome nanoparticle to the cells, and the targeting delivery capability of the liposome nanoparticle to the cells can be effectively improved. The nucleic acid delivery system can be applied to preparation of anti-tumor drugs.

The invention discloses a method for preparing a heterozygous exosome through DNA zipper mediated membrane fusion. A DNA zipper structure (ZDC / cZDC) modified by cholesterol is designed and anchored to the surface of a BMSC source exosome and the surface of a lipidosome membrane loaded with siRNA, membrane fusion is achieved through DNA complementary pairing, and after DNase I enzymolysis, the heterozygous exosome carrying siRNA and over-expressed CD146 at the same time is obtained. The method has the advantages of high fusion efficiency and uniform particle size, solves the problems of low drug loading efficiency and poor targeting property of the traditional exosome, and is suitable for gene-drug collaborative delivery.

Liposomes encapsulating a radioisotope can be used in the treatment of cancers including, but not limited to, leptomeningeal metastases. In an embodiment, liposome encapsulating a radioisotope comprising (186Re) obisbemeda can be administered to a patient through an Ommaya reservoir. The therapies can include imaging the liposome encapsulating a radioisotopе concomitant or subsequent to administration. Longitudinal analysis of the presence of tumor cells and biomarkers can be used to inform treatment strategy.

The invention relates to the technical field of biological medicine, and discloses a nano composite adjuvant as well as a preparation method and application thereof. The composite adjuvant mainly comprises a TLR9 agonist CpG ODN, a nanoscale liposome, a cationic lipid DOTAP and a high-efficiency immunologic stimulant QS-21, several adjuvant components are prepared into the stable and uniform nanoscale liposome by adopting a microfluidic synthesis method, CpG is wrapped inside the nanoscale liposome, QS-21 is adsorbed outside the nanoscale liposome, a stable immunologic stimulation compound is formed, and the immunologic stimulant can be used for immunologic detection of the TLR9 agonist CpG ODN, the cationic lipid DOTAP and the high-efficiency immunologic stimulant QS-21. All the components have a remarkable synergistic effect, and are matched with corresponding antigens to generate strong and lasting cellular immune and humoral immune responses.

The invention discloses an immunogenic composition containing a composite adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises a gE-gI fusion protein, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE-gI fusion protein comprises a VZV gE, a connecting peptide and a VZV gI. The immunogenic composition provided by the invention only contains one immunopotentiator, can be applied to VZV vaccines, and solves the problems of relatively weak gE immunogenicity and relatively large clinical side reaction of the vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, but the vaccine contains fewer immunopotentiators and has lower clinical side effects; in addition, the vaccine can also induce a gI specific antibody and gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. In short, the immunogenic composition has good clinical application potential.

Disclosed herein are synthetic nanoparticles, pharmaceutical compositions, kits, or methods for treating and / or preventing cancer. In some embodiments, the synthetic nanoparticles and / or pharmaceutical compositions comprises a pH sensitive liposome, an apolipoprotein, and andrographolide or derivative thereof. In some embodiments, the synthetic nanoparticles are delivered to a subject for treatment of cancer. In some embodiments, the cancer is T-cell lymphoma or B-cell lymphoma.

The disclosure generally provides biradial spherical nucleic acids (SNAs), compositions comprising a biradial SNA or a plurality thereof, and methods of making and using the biradial SNAs. In some aspects, the disclosure provides a biradial spherical nucleic acid (SNA) comprising: (a) a liposomal core comprising an outer leaflet and an inner leaflet; and (b) a population of oligonucleotides attached to the liposomal core, the population of oligonucleotides comprising: (i) a first plurality of oligonucleotides attached to the outer leaflet of the liposomal core and radiating outward from the liposomal core; and (ii) a second plurality of oligonucleotides attached to the inner leaflet of the liposomal core and radiating inward into the liposomal core, wherein one or more or all of the second plurality of oligonucleotides is a nuclease resistant oligonucleotide. In some embodiments, the first plurality of oligonucleotides and the second plurality of oligonucleotides are different.

The invention discloses a spleen-targeted nano platform construction method suitable for tumor vaccination, and particularly relates to the field of vaccines.The spleen-targeted nano platform construction method comprises the steps that S1, CL15H6-DOPS LNPs, spherical polymer vesicles and erythrocyte membrane coated nano-particles are selected as spleen-targeted nano-carriers; s2, integrating an immunologic adjuvant; mn < 2 + > doped LNPs, ultrasonic response lipidosome and a CD3 antibody are selected to be coupled to serve as an integration material; s3, delivering in vivo; animal models are selected for in-vivo delivery and curative effect verification, and B16F10 melanoma mice, MC38 colon cancer mice and non-human primates are selected as the animal models respectively. By optimizing the chain length and the surface topological structure (such as spherical polymer vesicles) of the liposome, the spleen enrichment rate is remarkably increased, and the red marrow myeloid cell uptake efficiency is enhanced. By combining with common delivery of a manganese adjuvant, an STING channel is activated, secretion of type I interferon is promoted, and the proportion of antigen-specific CD8 + T cells and the tumor inhibition rate are increased.

The compounds disclosed herein (e.g., compounds having a structure according to Formula (I), (II), (III), (IV), and (V)) are polymers wherein an organic polymeric segment (e.g., a polyethylene glycol (PEG) group) comprises covalent attachments to two or more lipid substructures, and each lipid substructure independently comprises a hydrophobic moiety and a hydrophilic moiety. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

A combination of lipid-binding molecules and / or lipid-binding proteins with lipid components (i.e., mispids) is provided for use in modifying the interaction between target molecules and lipid membranes. This includes, for example, the use of lipid-binding molecules and / or mispids to improve the sequencing efficiency and throughput of nanopore-based sequencing systems. To sequence target molecules such as nucleic acid sequences or nucleic acid substitute polymers derived therefrom, lipid-binding molecules and / or their mispids are combined with the target molecules. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of lipid-binding molecules and / or nanodiscs, thereby improving the capture, arrival time, and effective concentration of the target molecules across the chip membrane. Such improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.